Navigation Links
RBC Life Sciences Announces Third Quarter 2009 Results
Date:11/20/2009

IRVING, Texas, Nov. 20 /PRNewswire/ -- RBC Life Sciences, Inc. (OTC Bulletin Board: RBCL), a provider of proprietary nutritional supplements, wound care and pain management products, reported today company-wide net sales of $6.49 million for the quarter ended September 30, 2009, compared to net sales of $9.93 million for the same quarter last year.

The company also reported a net loss of $152,000, or $0.01 per share, during the third quarter of 2009, compared to net earnings of $846,000, or $0.04 per share, during the same quarter in 2008.

"The global economy has continued to impact sales, particularly with our international licensees," said RBC Life Sciences President and CEO John W. Price. "Domestically, we're starting to see positive returns from recent initiatives designed to grow North American network marketing sales. Sales in North America increased 11 percent during the third quarter, year over year. We also more than doubled our current Associate network base in this market during the first nine months of 2009."

Within the last year, RBC Life Sciences has launched a company-wide branding effort that encompassed everything from redesigned labeling and new, streamlined product offerings to a new Associate compensation plan. In August, RBC Life Sciences introduced an industry-first brain health product, NeuroBright. A recent animal study showed that NeuroBright increased subjects' learning and memory by nearly 50 percent.

The patent pending product was released at the same time RBC Life Sciences announced the ClearPay System, the industry's first virtually balancing flex compensation plan. The ClearPay System was designed to reward the company's Associates more quickly, more often and more abundantly compared to other compensation plans.

About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.





                            RBC Life Sciences, Inc.
                        Summary Results of Operations
                    (in thousands, except per share data)
                                 (unaudited)

                                            Quarters Ended September 30,
                                            ----------------------------
                                                   2009         2008
                                                   ----         ----

 Net sales                                       $6,487        $9,925
 Gross profit                                     3,215         4,710
 Operating profit (loss)                           (154)        1,387
 Earnings (loss) before income taxes               (195)        1,344
 Provision (benefit) for income taxes               (43)          498
 Net earnings (loss)                               (152)          846

 Earnings (loss) per share - basic and
  diluted                                        $(0.01)        $0.04

 Weighted average shares outstanding - basic     21,922        21,587
 Weighted average shares outstanding -
  diluted                                        21,922        22,906



                           RBC Life Sciences, Inc.
                        Summary Results of Operations
                    (in thousands, except per share data)
                                 (unaudited)

                                                   Nine Months Ended
                                                     September 30,
                                                  --------------------
                                                   2009          2008
                                                   ----          ----

 Net sales                                      $19,262        $23,160
 Gross profit                                     9,875         11,909
 Operating profit                                   192          2,499
 Earnings before income taxes                        68          2,367
 Provision for income taxes                         114            890
 Net earnings (loss)                                (46)         1,477

 Earnings (loss) per share
   Basic                                         $(0.00)         $0.07
   Diluted                                       $(0.00)         $0.06

 Weighted average shares outstanding - basic     21,920         21,315
 Weighted average shares outstanding -
  diluted                                        21,920         22,923





                          RBC Life Sciences, Inc.
                         Condensed Balance Sheets
                               (in thousands)
                                (unaudited)
                                 ----------

                                            September 30,   December 31,
                                            -------------   ------------
                                                2009            2008
                                                ----            ----
 Assets
 Cash and cash equivalents                     $3,518         $4,973
 Inventories                                    4,886          5,707
 Other current assets                           2,128          2,245
                                                -----          -----
   Total current assets                        10,532         12,925
 Other assets                                   7,346          6,841
                                                -----          -----
   Total assets                               $17,878        $19,766
                                              =======         ======

 Liabilities and shareholders' equity
 Accounts payable and accrued liabilities      $2,746         $3,228
 Deferred revenue                               2,843          4,279
 Other current liabilities                        153            144
                                                  ---            ---
   Total current liabilities                    5,742          7,651
 Other liabilities                              2,665          2,728
 Shareholders' equity                           9,471          9,387
                                                -----          -----
   Total liabilities and shareholders'
    equity                                    $17,878        $19,766
                                              =======        =======


SOURCE RBC Life Sciences, Inc.


'/>"/>
SOURCE RBC Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Human Pheromone Sciences Announces Third Quarter Results
2. Mineral BioSciences to Attend SupplySide West in Las Vegas
3. Sangamo BioSciences Reports Third Quarter 2009 Financial Results
4. FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC
5. Caliper Life Sciences Third Quarter 2009 Financial Results Conference Call Notice
6. Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
7. Elseviers Health Sciences Division and Peking University Medical Press cooperate on book donation
8. Magellan Biosciences Sells its Life Sciences Tools Business to Dionex
9. Somanetics Corporation To Present at UBS Global Life Sciences Conference and Maxim Group Growth Conference
10. Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City
11. Accera, Inc. to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... at a residential inpatient rehabilitation center can find some useful information in a ... located in Central Michigan. This video, which can be viewed on the Serenity ...
(Date:5/2/2016)... ... 02, 2016 , ... The Beryl Institute announces the publication ... international, open access, peer-reviewed journal focused on research and proven practices around understanding ... authors, the third volume of PXJ continues to expand PXJ's reach both with ...
(Date:5/2/2016)... Austin, Texas (PRWEB) , ... May 02, 2016 , ... ... return. As a token of appreciation, pet owners celebrate National Pet Week, which falls ... 7 in 2016, remind pet owners to cherish the human-animal bond and recognize responsible ...
(Date:5/2/2016)... ... 2016 , ... The Civilian Corps of the U.S. Army Medical Command (MEDCOM) ... for its uniformed service members, the retired service members, their families and other eligible ... May 12th National Nurses Week. It acknowledges the hard work and dedication of the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life Insurance ... understand life insurance throughout various life stages. , The site launched on April ... calculator and content specific to the times when life insurance matters most. , ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India , ... the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with policy ...
(Date:5/2/2016)... N.J. , May 2, 2016  Celsion ... development company, today announced data from the first ... escalating clinical trial (the OVATION Study) combining GEN-1, ... care for the treatment of newly-diagnosed patients with ... followed by interval debulking surgery.  In the first ...
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology: